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SUMMARY This review discusses the progress of ethnic genetics, the genetics of common diseases, and the con-
cepts of personalized medicine. We show the relationship between the structure of genetic diversity in human 
populations and the varying frequencies of Mendelian and multifactor diseases. We also examine the popula-
tion basis of pharmacogenetics and evaluate the effectiveness of  pharmacotherapy, along with a review of new 
achievements and prospects in personalized genomics. 
ABBREVIATIONS ADD – autosomal dominant diseases, ARD – autosomal recessive  diseases, HVSI – hyper -
variable segment I, mtDNA – mitochondrial DNA, CD – common diseases, RFLP – restriction fragments length 
polymorphism, IHD – ischemic heart disease, COLD – chronic obstructive lung disease, SNP – single nucleotide 
polymorphism, CNV – copy number variation, STR – short tandem repeats, HapMap – Haplotype Map of the Hu-
man Genome, CEU – population of Central European origin, YRI – population of Yoruba from Ibadan, Nigeria,   
CHB – Chinese population from Beijing, JPT – Japanese population from Tokyo, CMT1 – Charcot-Marie-Tooth 
disease, type 1, GWAS – genome-wide associations search, OR – odds ratio, OMIM – on-line Mendelian Inherit-
ance in Man catalogue.
PERSONALIZED MEDICINE
The concept of personalized medicine, which puts the 
individual patient, with all of his specific peculiarities, 
into the center of attention, is not new. The 19th-cen-
tury Russian physicians M.Y. Mudrov and N.I. Pirogov 
were well aware of this principle. “A doctor treats the 
patient, not the disease… Each patient needs special 
treatment depending on his physical constitution, even 
if the disease is the same,” wrote Mudrov. The great 
medical practitioners of the past also acknowledged the 
prophylactic value of personalized medicine – “Healthy 
people should be kept in hand… they should be advised 
on keeping to a healthy lifestyle” [1] and “a disease is 
easier to prevent than to treat” [2]. A new appreciation 
and the real potential for personalized medicine have 
re-appeared in the age of molecular genetics. By the end 
of the 1990s, a new concept of genomic medicine had 
started to take form [3, 4], and this concept involved “the 
routine use of genotyping methods, usually in the form 
of DNA-testing, for improving the quality of healthcare” 
[3]. The modern understanding of personalized medicine 
is based on the principles of preventive medicine, which 
were postulated by Nobel-prize laureate Jean Dausset 
[5]. The outlines of this concept are eloquently described 
by the 4P medicine principle or system medicine, which 
was suggested by Leroy Hood [6–8]. This principle states 
that “reactive” medicine (which reacts to a disease and 
fights its symptoms) must turn into predictive, prevent-
ative, personalized, and participatory medicine; namely, 
medicine that will be aimed at predicting the disease 
before it manifests itself through symptoms, take into 
account any individual (mainly genetic) traits of the pa-
tient, as well as involve the active help of the patient in 
identifying his or her genetic traits and in determining 
preventive measures. 
In Russia, ideas related to personalized medicine 
based on the advances in molecular genetics are being 
actively pursued at several genetic schools. One school, 
headed by RAMS full member V.P. Puzyrev [9-11], is 
developing the concept of genomic medicine. Another, 
headed by RAMS corresponding member V.S. Baranov 
[12-14], is developing the concept of genetic passports. 
ETHNIC GENETICS
The geographical region, ethnic group, and population 
largely determine the genetic traits of an individual. 
Setting aside the issues of the substance, the termino-
logical and meaningful differences in the geographic, 
ethnic and population levels of gene-pool organization, 
we shall review these terms in the context of personal-
ized medicine in which they are essentially synonymous 
– they reflect the individual traits of a human that are 
dependent on his genetic origins. 
It is agreed that a detailed understanding of genetic 
diversity in human populations is crucial for deter-
mining the genetic basis of most common diseases [15]. 
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Approaches aimed at identifying genetic similarities 
between various ethnic groups and populations, and 
which involve the study of polymorphic genetic mark-
ers, have been used in evolutionary and population 
genetics since the middle of the 1950s. Initially, pro-
tein polymorphisms played the role of genetic mark-
ers [16–18]. However, as molecular genetic techniques 
improved, population studies were reoriented toward 
various classes of DNA markers, with non-recombinant 
lineages of mtDNA and Y-chromosomes being the most 
widely used [19–21, etc.]. These studies allowed re-
searchers to form an understanding of the main stages 
of population spread and of the ethnic divergence of 
modern humans. This also resulted in the appearance of 
a new scientific field: ethnogenetics. According to Bal-
anovsky and Rychkov [22], ethnogenetics is a branch of 
population genetics which “pays special attention to the 
ethnic structure of populations and attempts to identify 
the genetic results of the ethno-historic and ecological 
development of human populations.” 
Currently, the most useful tools for describing genet-
ic variability in various ethnic groups and populations 
are genome-wide sets of single nucleotide polymor-
phisms (SNPs), which are sometimes complemented 
by copy number variability (CNV) data [23–26, etc.]. 
A promising method that is sure to be used in years to 
come is the re-sequencing of complete genomes in rep-
resentative cohorts from different populations. 
Studies in ethnogenetics are among the most produc-
tive areas of genetic science in Russia, and such stud-
ies are being actively pursued in a number of research 
facilities [27–31]. 
The importance of population genetics for personal-
ized medicine also derives from the fact that knowledge 
of the role of genetic variability in the pathogenesis of 
common diseases can only be obtained by a detailed 
analysis of the associations between genetic markers 
and diseases on large cohorts of patients and healthy 
people from various populations. Specifically, one of the 
most productive approaches for association analysis, 
the so-called Genome-wide Association Study (GWAS), 
requires the testing of hundreds, if not thousands, of 
individuals and replication of the discovered associa-
tions in other populations. 
The cooperative development of ethnic genetics, the 
genetics of common diseases, and the concept of per-
sonalized medicine spawns a number of key questions. 
Answers to these questions will determine to what use 
and how quickly genetics will be adopted in predictive 
medicine:
- How marked are interethnic differences in disease 
incidence and disease susceptibility gene frequencies?
- What are the evolutional mechanisms behind the 
differences in disease gene frequencies?
- Do racial, ethnic or geographical origins influence 
the impact of distinct genetic variants on the course of 
a disease?
- To what degree does genetic diversity account for 
the differences in the spread and outcome of diseases 
between racial and ethnic groups? 
- Is there any need for information on the racial/eth-
nic origin of patients for medical research?
Drawing up a picture of the current understanding 
of the answers to these questions is the main aim of this 
article. 
STRUCTURE OF GENETIC VARIABILITY 
IN HUMAN POPULATIONS
How different are human populations genetically? Human 
population genetics give a precise answer to this question 
– interpopulation differences in a global sense (comparing 
the populations of different continents) are responsible 
for 10–15% of the genetic variability in humans (Table 1). 
In other words, the Wright Fixation Index (Fst) is 0.10-0.15 
Table 1. Genetic Differentiation of Human Populations
Marker type Populations FST Reference
Classical markers
Blood types World 0.16 [40]
Protein polymorphism World 0.11 [40]
DNA-markers
RFLP -“- 0.11 [21]
dinucleotide -“- 0.11 [41]
trinucleotide -“- 0.04 [42]
tetranucleotide -“- 0.04 [21, 43]
Microsattelites and RFLP -“- 0.15 [44]
Alu-repeats -“- 0.12 [45]
Alu-repeats -“- 0.10 [46]
mtDNA HVSI -“- 0.14 [47]
Y-chromosome, haplo-
groups
North 
Eurasia 0.19 [28]
Y-chromosome STR North 
Eurasia 0.19 [28]
Genome-wide marker sets
600К SNP YRI, CEU, 
JPT, CHB 0.12 [48]
1 million SNP YRI, CEU, 
JPT, CHB 0.10 [48]
1 million YRI, CEU, 
JPT, CHB 0.13 [49]
440K SNP World 0.05 [26]
50K SNP Asia 0.06 [25]
2.8 million YRI, CEU, 
JPT, CHB 0.11 [50]
244K SNP World 0.12 [51]
200K SNP World 0.13 [33] 
67 CNV World 0.11 [52]REVIEWS
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when estimating the global level of genetic differentia-
tion in human populations. This interval includes values 
obtained for most systems of genetic markers in classi-
cal and molecular population genetics of humans -- blood 
type, protein polymorphism, RFLP, Alu-repeats, hy-
pervariable segments of mtDNA [28, 32]. Exceptions are 
the highly mutable microsatellites (STR), whose level of 
genetic differentiation is much lower (4–5%), and the Y-
chromosome, whose variants differ (20-30%) between 
populations much more than other marker systems. These 
two types of markers are so distinctly different because of 
specific evolutional, population, and social mechanisms 
we will not discuss in this work (see [28]). 
A relatively low level of genetic subdivision in hu-
man populations can be observed in the most repre-
sentative and complete sets of markers – on large and 
random datasets of autosomal polymorphisms, includ-
ing genome-wide sets of hundreds of thousands of 
SNPs. Li et al. [24] analyzed data for 650,000 SNPs in 
51 populations obtained from the Human Genome Di-
versity Project (HGDP) and found that interpopulation 
differences accounted for 11% of overall genetic diver-
sity. Recent work by us yielded another estimate of the 
genetic differentiation in 36 populations (32 Eurasian 
populations and 4 HapMap populations) for 200,000 
SNPs, the result being 13.4% [33]. Somewhat smaller 
genetic differences were observed during the analysis 
of a lower number of continental groups. The level of 
genetic differentiation between populations in Asia is 
5.9% according to data from the Panasian SNP Consor-
tium [25], while the population differentiation in East 
Asia, South Asia, Europe, and Mexico is 5.2% [26]. 
The low level of genetic differentiation in human 
populations as compared to related species (chimpan-
zees (FST = 0.32) [34] and gorillas (FST = 0.38) [35]), de-
spite the much larger population area, indicates that 
the human population originated relatively recently 
from a small number of ancestors. 
The most general distribution pattern of human 
population diversity is its strict geographical struc-
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ture, namely the clustering of geographically adjacent 
populations. On a worldwide scale, populations can be 
grouped into racial-continental groups for any set of 
markers. These groups are African Negroids, Cau-
casoids (which are divided into the Middle Eastern, 
European, and Indian sub-clusters), Asian Mongol-
oids, Austronesians, and American Indians [24, 25, 36] 
(Fig. 1). This pattern can also be observed on a smaller 
scale - for continental and subcontinental groups of 
populations [23, 37]. The projection of genetic differ-
ences between representative population datasets onto 
a space of major components or factors always yields a 
geographical map at first approximation. The cause of 
such a distribution is the evolutionary history of genet-
ic diversity, which resulted mainly from migration and 
genetic drift during the spread of modern humans.
The population of Russia is not exempt from this 
pattern. Russian populations cluster into several large 
ethnogeographical groups: Slavs, Northern Caucasus 
populations, Finno-Ugric peoples of the North Euro-
pean and Volga-Ural regions, the populations of South 
Siberia and Central Asia, and the populations of East-
ern Siberia and North Asia [28, 33]. The geographical 
structure of the Russian gene pool can be observed 
for all of the genetic markers – lineages of mtDNA, Y-
chromosomes, X-chromosomes, and autosomal mark-
ers, including complete genomic sets of SNPs.
It is probable that the only major exception to the 
“geographical pattern” is the Indian subcontinent, in 
which the genetic diversity is better correlated to the 
language group, rather than the geographical origin. 
This is due to the complex ethnic and social structure of 
the population, caste hierarchy of large ethnic groups, 
and the presence of numerous small clan/tribe groups 
[38, 39].
How different are human populations in terms of dis-
ease incidence and disease gene frequency?
If we assume that the question of general interpopula-
tion genetic diversity in humans has been answered, 
then the following questions arise: To what degree is 
genetic variation correlated with phenotypic variation, 
especially for clinical phenotypes (diseases)? To what 
degree are the differences in disease gene frequencies 
responsible for the interethnic and interpopulation dif-
ferences in disease incidence? The first question can 
be answered using data on genetic epidemiology and 
medical statistics, while the second question needs spe-
cial approaches. 
Ethnic component of monogenic diseases
Genetic epidemiology has collected a large set of data 
on the frequency of Mendelian (monogenic) diseases 
in various populations. The overall load of hereditary 
diseases (HD) (the summed frequencies of autosomal 
dominant, autosomal recessive and X-linked diseases) 
in stable populations is relatively low and varies in a 
narrow range from 1.5 to 3.5 cases per 1,000 (Fig. 2). For 
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instance, 10 Russian populations including Slav, Fin-
no-Ugric, and North Caucasus populaces vary in their 
summed HD load from 1.59 per 1,000 in the cities of the 
Kirovsk region to 3.5 per 1,000 in rural Mari popula-
tions [53]. A similar variability of HD loads is observed 
in the native populations of Siberia [54, 55]. However, 
some forms of HD can vary in much wider intervals. 
For instance, the incidence of cystic fibrosis can vary 
up to 10-fold in different regions of Siberia [56]. 
In the case of HD, differences in disease incidence 
are directly linked to differences in the allele frequen-
cies in the population. The main factors behind popula-
tion dynamics, which form the overall picture of inter-
population differences in an HD load, are genetic drift 
and the founder effect [53]. Drift plays a leading role 
even when the size of the population is stable, and its 
effect is compounded by rapid changes in the effective 
population size (population waves). Overall, the role of 
natural selection in the HD gene differentiation of pop-
ulations is small, since mutations that lead to HD lower 
the fitness  of individuals, irrespective of ethnicity or 
geographical origins. 
However, there are several interesting exceptions to 
this rule. The most well-known is the high number of 
individuals that are heterozygous for sickle-cell ane-
mia and β-thalassemia in subtropical and tropical re-
gions, such as the Mediterranean. Regions where these 
erythrocyte diseases occur frequently are virtually 
identical to those where malaria incidence is high [57]. 
Heterozygous carriers of the mutant alleles have a se-
lective advantage due to their higher level of resistance 
to malaria, and the high frequency of heterozygotes is 
supported by balancing selection. 
Another common hereditary disease, cystic fibrosis, 
occurs frequently among Europeans and is much less 
common in other geographical regions. The wide spread 
of the main mutation (ΔF508) across all of Europe and 
its rarity in other parts of the world indicate that this 
mutation appeared a long time ago, sometime after the 
migration of modern humans from Africa. Direct esti-
mates of the mutation’s age using various methods sug-
gest the opposite: namely that the mutation appeared 
relatively recently, about 10 thousand years ago [58, 
59]. The likely reason for the wide spread of this muta-
tion in Europe, just as for the erythrocyte diseases, is 
the lower susceptibility of ΔF508 heterozygotes to de-
hydration during typhoid and cholera, which remained 
a common menace in Europe until recently. 
Local adaptation of populations to dietary products 
can also lead to differentiation for certain diseases. 
Thus, the high incidence of the celiac disease in North-
ern Europe, especially in Scandinavian countries, and 
low incidence in Southern Europe are likely connected 
to the longer history of agriculture, specifically cereal 
plant cultivation, in the south of Europe and the preva-
lence of game as the main source of food for the Scandi-
navian population, which would mean that there were 
virtually no cereals in their diet. 
The role of genetic drift and the founder effect in the 
spread of HD can be illustrated well by the accumula-
tion of certain forms of hereditary pathologies in some 
populations. Well-known examples of such populations 
are the Finns, Ashkenazi Jews, French Canadians and 
the Amish peoples. More than 20 so-called “Finnish” 
diseases have been documented - these are HD (mostly 
autosomal recessive), whose incidence among Finns is 
much higher than among other populations [60, 61]. 
The phenomenon of HD accumulation in the Finnish 
population is due to effective drift, long-term genetic 
isolation, and high occurrence of inbreeding. The same 
population mechanisms were probably the reason be-
hind the accumulation of certain HD genes among the 
Ashkenazi Jews. They were also observed to have an 
extremely high incidence of more than 20 diseases (the 
most common among these being the Tay–Sachs dis-
ease and Type I Gaucher’s disease) [62].
In Russian populations, the phenomenon of ethno-
specific diseases is most often seen in Yakuts (Table 2). 
As many as 6 diseases can be termed “Yakut,” since the 
frequency of these diseases is above mean global fre-
quencies by as much as several ten-fold. These diseases 
include two types of dwarfism which have been docu-
mented only recently [63, 64]. The population mechanism 
behind this accumulation of HD in Yakut groups is the 
founder effect, which coincided with some of the waves 
of expansion and migration of the Yakut people.
Overall, some Mendelian HD can exhibit consider-
able interethnic frequency differences, which are due 
to differences in the frequency and type of mutations. 
These traits must, of course, be taken (and are taken) 
into account during medico-genetic counseling, DNA-
diagnostics, and screening programs. In this context, 
DNA-diagnostics of HD can be considered as the first 
real use of personalized genomic medicine. 
Genetic diversity and complex diseases. GWAS
Interpopulation comparisons of the frequencies of com-
mon multi-factor diseases (MFD),  also known as com-
plex diseases, are complicated by the absence of ho-
mogenous medical statistics for global populations and 
the considerable clinical and genetic heterogeneity of 
MFD. However, there is a considerable amount of data 
on the interpopulation differences in the occurrence of 
MFDs, such as cardio-vascular diseases [68, 69], diabe-
tes [70], some types of cancer [71], glaucoma [72], and 
nephropathies [73]. 
The U.S. population can act as a good model for com-
paring the incidence of complex diseases: it is a multira-20 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
REVIEWS
cial country with a highly developed healthcare system 
and thorough medical statistics. Table 3 shows mortali-
ty data from the National Center of Statistics in Health-
care for the four main ethno-racial groups of the U.S. 
population - white Americans, African Americans, His-
panics from Latin America, and Asian Americans [74]. 
Since the overall mortality per 100,000 varies consider-
ably (this value is twice higher for African Americans 
as compared to Latino Americans and Asians, while the 
mortality of the white population is intermediate), we 
recalculated these data as fractions of the overall value 
for each cause of death in each ethnic group. The right-
hand side of the table lists ratios between the mortali-
ties from various causes in three minor ethnic groups 
and white Americans. These data allow us to conclude 
that the two main causes of death in the U.S., namely 
cardiovascular and oncological diseases, which are re-
sponsible for half of the mortality rate, do not display 
any significant interracial differences. Other disease 
groups sometimes display considerable racial differ-
ences. Thus, the relative mortality due to diabetes is 
about 1.5 times higher for African Americans as com-
pared to white Americans, while the mortality due to 
IHD (ischemic heart disease), chronic lung, and kid-
Table 2. Ethno-specific diseases in Yakuts
Diseases 
(OMIM number)
World prevalence 
(1 per 100,000)
Prevalence in Yakuts 
(1 per 100,000) References
Spinocerebellar ataxia type 1 (164400) 1.0 38.6 [65]
Myotonic dystrophy (160900) 4.0-5.0 21.3 [66]
Inherited enzymopenic methaemoglobinaemia (250800) 1.0 5.7 [67]
Oculopharingeal muscular dystrophy (164300) 1.0 11.1 [63, 64]
3M syndrome (Yakut short stature syndrome) (273750) 25 cases 12.72 [64]
Syndrome of short stature with cone dysfunction, optic atrophy, 
and Pelger-Huet anomaly (SCOP) (not present in OMIM) Not described 9.95 [64]
Table 3. Mortality rates in 4 major racial groups in U.S.1
Relative share in overall mortality  
inside the racial group Mortality relative to White Americans2
Cause of Death Whites African 
Americans
Latino 
Americans Asians African 
Americans
Latino 
Americans Asians
Heart disease 27 26.6 25.3 25.5 0.98 0.94 0.94
Coronary heart disease 17.6 139 16.4 16.2 0.79 0.93 0.92
Stroke 52 6 5.7 8.6 1.15 1.09 1.65
Chronic obstructtive 
pulmonary diseases 4.9 26 2.5 2.8 0.53 0.51 0.57
Cancer 268 23.3 22.8 28.3 0.87 0.85 1.05
Pneumo-nia / Influenza 2.8 2.5 2.9 3.9 0.89 1.03 1.39
Liver diseases / Cirrhosis 1.6 1.1 3.5 0.9 0.69 2.18 0.56
Diabetes 2.7 4.2 5.5 3.3 1.55 2.03 1.22
HIV infection 0.6 3 1.8 0.3 5 3 0.5
External causes 10.4 9.9 13.4 9.2 0.95 1.29 0.88
All causes (per 100000) 450.4 690.9 332.8 264.6
Notes. 
1According to National Center for Health Statistics [74]. 
2Mortality rate in White Americans is taken as 1.REVIEWS
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ney diseases is much lower for African Americans. The 
relative mortality due to diabetes and kidney diseases 
among Hispanic Americans is more than twice as high 
compared with white Americans, while the mortality 
due to chronic lung diseases is twice as low. Asians die 
from strokes and pneumonia much more often than 
do white Americans; however, mortality due to COPD 
(Chronic Obstructive Pulmonary Disease) and kidney 
diseases is half as common in Asians as it is in white 
Americans. 
To what extent can such differences be attributed to 
interethnic genetic differentiation? Important informa-
tion on this subject can be obtained by analyzing the 
associations of genetic markers with complex diseases, 
including genome-wide association searches. 
Ioannides et al. [75] compared the frequencies of ge-
netic markers and their effects on diseases in the Euro-
pean, Asian, and African populations. They conducted 
a meta-analysis of 135 gene-disease associations, 45 of 
which proved to be statistically significant either on 
the level of a general meta-analysis (32 associations), 
or at least at the level of a single racial group (11 as-
sociations). The data of 45 meaningful meta-analyses 
encompassed 697 individual association studies with 
a combined cohort size of 300,000 individuals. The au-
thors detected a statistically significant heterogeneity 
of the disease-associated allele frequencies (i.e. mean-
ingful interpopulation differences) for 58% of the gene-
disease associations. Significant differences in OR (odds 
ratio, a measure of the genetic risk of disease incidence) 
were detected only in 14% of the meta-analyses. No-
tably, interracial comparisons did not yield any sig-
nificant associations with opposite effects in different 
populations. 
These data indicate that the differences in suscepti-
bility gene frequencies may be one of the causes behind 
the interethnic differences in MFD incidence. However, 
the biological effect of the associated alleles is unidirec-
tional, irrespective of the racial/ethnic origins, even 
though the relative share of the marker in the disease 
or susceptibility can vary. This is most probably due 
to the genotype (haplotype) surroundings, as well as 
gene-gene and gene-environment interactions. 
In recent years, the main source of new data con-
cerning MFD susceptibility genes has been genome-
wide association studies (GWAS). GWAS requires high-
throughput analysis, which is achieved by using large 
cohorts (several hundreds or thousands) representa-
tive of the population, and a large number (hundreds 
of thousands) of tested polymorphisms, which are rep-
resentative of the genomic diversity. A catalog of pub-
lished GWAS is supported by the U.S. National Insti-
tute of Genomic Research and includes GWAS which 
were performed under very strict criteria: no fewer 
than 100,000 SNP must be analyzed, and the level of 
significance of a SNP-trait association must be no lower 
than 0.00001 [76]. As of the end of March 2010, the cata-
log contains 527 published studies and 2,516 SNP that 
are reliably associated with complex phenotypes. 
A major part of these GWAS have been conducted 
on European populations, and no reliable estimations 
of the interethnic differentiation of disease-associated 
genome regions can be made using GWAS data alone. 
Adeyemo and Rotimi [77] managed to skirt this prob-
lem by analyzing the genetic heterogeneity of markers 
chosen from the GWAS catalog in populations from the 
HapMap project. The HapMap project (a map of human 
haplotypes) currently contains data on the polymor-
phism of several million SNP and the level of linkage 
disequilibrium across the whole genome for 11 popula-
tions of various ethnic origins, which are representative 
of the world population (Europeans, Asians, Africans, 
Indians, and Latin Americans). Adeyemo and Rotimi 
chose 621 SNPs from the GWAS catalog, which were 
associated with 26 complex diseases, including Alzhe-
imer’s disease, hypertension, obesity, schizophrenia, 
type I and type II diabetes, rheumatoid arthritis, cer-
tain types of cancer, etc. The allelic frequencies of the 
chosen SNPs varied across the populations in a relative-
ly wide range - differences of up to 20 to 40-fold were 
observed between some pairs of population groups. The 
interpopulation genetic diversity ratio (Fst) also varied 
considerably from marker to marker (such as, from 0.02 
to 0.2 for type II diabetes or from 0.006 to 0.52 for the 
level of lipids). The mean level of interpopulation dif-
ference was 10.5%; i.e., it did not significantly differ 
from the differentiation level observed for condition-
ally neutral or genome-wide datasets of markers.
 These data suggest that the level of interpopulation 
and interethnic differences for genes associated with 
MFD does not differ from the general level of differen-
tiation in the gene-pool, and that the risk of develop-
ing a disease associated with a genetic marker can vary 
significantly between population groups, depending 
on the frequencies of the associated marker and the 
modulating effects of other genes and environmental 
factors. 
The role of gene-gene and gene-environment inter-
actions is usually hard to differentiate; however, their 
overall effect in the modification of disease risk asso-
ciated with a certain gene or marker can be very sig-
nificant and has population specificity. As an example, 
we can examine data for the role of the ε4 allele of the 
APOE gene in Alzheimer’s disease (AD). Reliable as-
sociation of this marker with AD has been observed for 
all of the tested race groups; however, the frequency of 
the allele differs considerably (9% among the Japanese 
population, 14% among white Americans, 19% among 22 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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African Americans). Homozygozity for the ε4 allele in-
creases the risk of AD 33-fold for Japanese, 15-fold for 
white Americans, and only 6-fold for African Ameri-
cans. For heterozygous individuals these values are cor-
respondingly 5.6–3–1.1.  
Thus, even if the risk of complex disease develop-
ment is reliably associated with distinct genetic mark-
ers in all populations and these markers have unidi-
rectional effects, the magnitude of the effect or the 
severity of the risk still greatly depends on ethnicity- 
and population-specific factors of genetic and prob-
ably non-genetic nature. So, data on ethnic origins can 
provide additional information in making personalized 
medical prognoses. 
ETHNOGENETICS AND PHARMACOGENOMICS
One of the main advantages of personalized medicine 
is the individualization of drug therapy. Response to 
a drug, choice of the optimal drug class, dosage, and 
usage schedules can, at least partially, be determined 
using genetic factors. Information on individual genetic 
markers can help a clinician select the appropriate drug 
strategy. Based on these principles, pharmacogeneti-
cists attempt to identify the genes and gene variants 
that influence the efficiency of drug therapy and lower 
the risk of side effects. It has been shown that the most 
widely used drugs are only effective in 25-60% of pa-
tients, and there have been 2 million cases of side ef-
fects per year in the U.S. alone, including more than a 
100,000 deaths [78]. 
Pharmocogenomics studies have collected consider-
able data on the association of genetic markers with the 
effectiveness of certain drugs. During the last 20 years 
there have been approximately 2,000 studies on this 
subject, and hundreds of genes associated with drug 
therapy efficiency have been identified [79]. Most of 
these pharmacogenetics studies concern cardiovascu-
lar, oncological, and neurological diseases. 
The FDA (Food and Drug Administration) of the U.S. 
Ministry of Healthcare has approved the addition of ge-
netic marker information into the annotations of about 
30 drugs, including warfarin, abacavir, imatinib, ator-
vastatin, etc. [80]. The list of biomarkers which were 
appended into these annotations includes genes that 
encode cytochromes, a low density lipoprotein receptor, 
N-acetyltransferases, epidermal growth factor recep-
tor, etc.. The effects of drug therapy that depend on 
the genotypes for these markers include the clinical re-
sponse to therapy, risk of side effects, choice of optimal 
dosage, sensitivity or resistance towards the drug, and 
polymorphism of drug targets.
Most of the relevant pharmacogenetic data has been 
collected on Caucasoids - more than 80% of the pub-
lished research has been conducted on the European 
and U.S. populations [80], which is why there is little 
information on the interethnic differences of drug effi-
ciency and on the role of genetic factors. As an example, 
we can note the decreased effectiveness of enalapril, 
weakened effect of the vasodilator sodium nitroprus-
side (an antihypertnesion vasodilator), and decreased 
effect of propranolol and atenolol (adrenoreceptor 
blockers) during hypertension therapy for African 
Americans as compared to Caucasians [81]. In some cas-
es, the interethnic differences can be associated with 
frequency differences for a specific marker. Thus, the 
difference in propranolol and atenolol efficiency is due 
to the higher frequency of one of the missense muta-
tions of the β1-adrenoergic receptor in white Ameri-
cans (72%) as compared to African Americans (57%). 
We can surmise that interracial and interethnic dif-
ferences in the effectiveness of drug therapy can be 
as common as interpopulation differences in MFD fre-
quencies, since the genetic variability of genes that me-
tabolize therapeutic drugs is the same as that of com-
plex disease susceptibility genes [82, 83]. For instance, 
there is a 10-fold difference in the frequency of slow 
metabolizing variants of cytochrome CYP2D6 between 
Caucasians and Asians (10% for Caucasians and 1% for 
Japanese). This enzyme is involved in the metabolism of 
over 40 drugs, such as the widely used β-blockers and 
tricyclic antidepressants. The frequency of extremely 
fast metabolizing alleles of this enzyme exhibits a 10-
fold difference even inside Europe - about 1-2% in 
Spain and up to 10% in Sweden. Our data also indicate 
a considerable variability within Russian populations 
in terms of drug metabolizing genes. For instance, the 
frequency of the CYP2C9*2 allele of one of the cyto-
chrome genes is 12% for Russians, which is within the 
variability interval observed for Europeans (10–17%), 
while the allele is not present in Eastern Asian popu-
lations and occurs in the native populations of Siberia 
with a frequency of 1 to 6% [83]. The overall level of ge-
netic differentiation for cytochrome genes is relatively 
low (Fst = 0.021) in Russian populations; however, it is 
tightly correlated with the geographical layout, as are 
most other marker systems (Fig.3). 
FROM THE HUMAN GENOME TO 
THE INDIVIDUAL GENOME 
Re-sequencing of complete individual genomes yields 
new data on the genetic variability of humans and can 
help create individual health prognoses in the future. 
The first personal genome to be sequenced was the 
genome of Craig Venter, one of the key figures in the 
study of the human genome. Venter’s genome sequence 
was completed in October 2007 [84]. Data on the second 
sequenced genome (of Nobel Laureate James Watson) 
were published half a year later [85]. Currently (from REVIEWS
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the middle of 2010), there are data on 20 re-sequenced 
genomes (Table 4), which include those of Craig Venter, 
James Watson, archbishop Desmond Tutu, the twice-
sequenced genome of a Yoruba individual, a Chinese 
genome, two Koreans, several Europeans, an ancient 
Eskimo, a Russian, and an Indian [84–99]. 
Apart from the complete genomes of unrelated 
healthy people of various descents and renown, re-
searchers have also obtained complete sequences of 
patients with monogenic diseases: these include four 
genomes of a family quartet in which the children 
suffer from Miller syndrome (primary ciliary diski-
nesia in a lung form, which is phenotypically similar 
to cystic fibrosis) [98], a as well as a genome of a type 
I Charcot–Marie–Tooth disease patient [97]. No less 
than 7 complete tumor cell genomes have been pub-
lished for cancers of various localizations: acute my-
eloid leucosis, malignant melanoma, glioblastoma, etc. 
[86, 100–105].
Progress in sequencing technology has been colossal 
in terms of speed and cost reduction. The sequencing of 
Venter’s genome, which was conducted on first genera-
tion sequencers, cost his company about 2 million U.S. 
dollars. Genomes which are sequenced on second-gener-
ation machines (Illumina Genome Analyzer and Applied 
Biosystems Solid System) cost about 200–500,000, while 
the most recent studies involving the re-sequencing of 
complete genomes cost no more than 1,500 U.S. dollars. 
So, Francis Colins’ [106] prognosis in 2001that the cost of 
sequencing a genome would fall to 1,000 dollars by 2030 
has come to pass 20 years ahead of time!
The “1,000 genomes” project is aimed at obtaining 
complete and accurate genome sequences of 2,000 in-
dividuals from different populations of the main geo-
graphical regions of the world (Africa, Europe, Asia, 
and the Americas) [107]. During the first phase of the 
project, 180 samples from four HapMap populations 
(CEU, YRI, CHB, and JPT) were sequenced, albeit with 
only a few repetitions (2-8). 
What new knowledge do personal genomes add to 
the understanding of human genetic variability and 
what is their use in personalized medicine? First of 
all, researchers discover new genetic variants – each 
genome has about 2.5–4 million SNPs, several thou-
sands of insertions/deletions and several hundreds or 
thousands of CNVs (Table 2). Most of these variants are 
being described for the first time. Re-sequencing data 
from complete genomes confirms the level of individual 
variability observed for the genomes sequenced in the 
“Human Genome” project - on average 3 million SNP 
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Table 4. Personal genomes chronology
  Date of publication 
(submission) Person Journal Institution (country) Platform Cove-
rage
Number 
of SNPs 
(millions)
Notes
1.  2007, October  
(9 May 2007) Craig Venter (m) PloS 
Biology, [83]
J Craig Venter 
Institute (U.S.) ABI 3730xl 7.5 3.47  $10 mln
2.  2008, April
(3 December 2007)
James Due Watson 
(m) Nature [84]
Baylor College of 
Medicine / 454 Life 
Sciences (U.S.)
Roche / 454 7.4 3.32  $2 mln
3. 2008, November 
(28 May 2008)
Caucasian 
American with 
acute myeloid 
leukemia (normal 
fibroblasts) (f)
Nature [85] University of 
Washington (U.S.) Illumina 13.9 2.92 $1 mln
4.  2008, November 
(24 June 2008)
Yoruba (NA18507) 
(m) Nature [86] Illumina / University 
of Cambridge (UK) Illumina 41 3.45 $250,000
5.  2008, November 
(21 August 2008)
Chinese 
(Yanhuang, YH) 
(m)
Nature [87] Beijing Genomic 
Institute (China) Illumina 36 3.07 $500,000
6. 2009, May 
(3 February 2009)
Korean Seong-Jin 
Kim, SJK (m)
Genome 
Research  
[89]
Gachon University of 
Medicine and Science 
(Rep. of Korea)
Illumina 29 3.44
7.  2009, June 
(1 February 2009)
Yoruba (NA18507) 
(m)
Genome 
Research 
[90]
Life Technologies 
(U.S.) ABI SOLiD 17.9 3.87
8. 2009, August 
(6 March 2009) Korean, AK1 (m) Nature [91]
Seoul National 
University (Rep. of 
Korea)
Illumina 27.8 3.45
9. 2009, August
(10 June 2009)
Steven Quake, 
Caucasoid USA, 
P0 (m)
Nature 
Biotechnol 
[92]
Stanford University 
(U.S.)
Helicos SMS 
Heliscope 28 2.81
Sequence 
from 1 
molecule
$48,000
10. 2009, December Russian with 
kidney cancer (m)
Acta 
Naturae, 
[93]
RNC Kurchatov’s 
Institute (Russia)
Illumina/ABI 
SOLiD  16 ?
11. 2010, January 
(3 September 2009)
Caucasoid 
(NA07022) (m) Science [94] Complete Genomics 
(USA)
Complete 
Genomics DNA 
nanoarray
87 3.08 $8,000
12. 2010, January 
(3 September 2009)
Yoruba (NA19240) 
(f) Science [94] Complete Genomics 
(U.S.)
Complete 
Genomics DNA 
nanoarray
63 4.04 $3,400
13. 2010, January 
(3 September 2009)
Caucasoid 
(NA20431) (f) Science [94] Complete Genomics 
(U.S.)
Complete 
Genomics DNA 
nanoarray
45 2.91 $1,700
14.
2010, February 
(30 November 
2009)
Paleo-Eskimo, 
Saqqaq (м) Nature [95]
University of 
Copenhagen / Beijing 
Genomic Institute 
(Denmark / China)
Illumina 20 2.19
Ancient 
DNA 
(4000 
years)
15. 2010, February  
(11 August 2009) Khoisan, KB1  (m)  Nature [96] Pennsylvania State 
University (U.S.)
Roche / 454 / 
Illumina 33.4 4.05
16. 2010, February  
(11 August 2009)
Bantu, ABT 
Archbishop 
Desmond Tutu (m)
Nature [96] Pennsylvania State 
University )
ABI SOLiD / 
Illumina 37.2 3.62
17. 2010, March Caucasoid,  CMT1 
patient (m)
New Eng J 
Med [97]
Baylor College of 
Medicine (U.S) ABI SOLiD 29.9 3.42
18. 2010, March  
(7 January 2010)
Pedigree #1, 
mother (Caucasoid, 
f)
Science [98]
Institute for System 
Biology / Complete 
Genomics (U.S.)
Complete 
Genomics DNA 
nanoarray
51 2.87
19. 2010, March (7 
January 2010)
Pedigree #1, 
father (Caucasoid, 
m)
Science [98]
Institute for System 
Biology / Complete 
Genomics (U.S.)
Complete 
Genomics DNA 
nanoarray
88 3.16
20. 2010, March  
(7 January 2010)
Pedigree #1, 
daughter 
(Caucasoid, f, 
patient with Miller 
syndrome)
Science [98]
Institute for System 
Biology / Complete 
Genomics (U.S.)
Complete 
Genomics DNA 
nanoarray
54 3.23
21. 2010, March (7 
January 2010)
Pedigree #1, son 
(Caucasoid, m, 
patient with Miller 
syndrome)
Science [98]
Institute for System 
Biology / Complete 
Genomics (U.S.)
Complete 
Genomics DNA 
nanoarray
52 3.23
22 2010, September 
(10 April 2010) Irish Genome 
Biol [99]
University College 
Dublin (Ireland) Illumina 11 3.12REVIEWS
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from a 3 billion base genome yield differences in 1 nu-
cleotide in a thousand. 
The genomes of two individuals overlap for about 
half of the SNPs (Table 5). The degree of relation be-
tween the genomes is correlated with the genetic dif-
ferentiation between the populations to which these 
genomes belong. The Yoruba genome is the farthest re-
moved from others (38–45% overlapping SNPs), while 
the most related genomes are those of а Chinese and 
Korean (60–67% overlapping SNPs). 
“Overlaying” the variable positions in complete ge-
nomes onto the data obtained in large-scale population 
projects (such as HapMap) allows us to glimpse at the 
genetic origins of an individual. For instance, by com-
paring SNPs in the Venter, Watson, and YH Chinese 
genomes with four HapMap populations (Fig. 4), based 
on the marker distributions in populations CEU, YRI, 
CHB, and JPT, researchers can estimate the level of 
cross-breeding between the main racial and ethnic 
components observed in these genomes. Thus, the 
shares of Caucasoid, Negroid, and Mongoloid compo-
nents in Venter’s genome were estimated at 93.3, 5.1, 
and 1.6% respectively. The genome of the Nobel-prize 
winner Watson had a lower share of Caucasoid SNP 
(73.0%) due to the increased amount of Negroid mark-
ers (25.6%).
A personal genome sequence provides complete in-
formation on whether the individual carries any alle-
les associated with clinical phenotypes and is thus ex-
tremely valuable for individual health prognoses and 
for estimating MFD risks. The precision and relevance 
of the genetic health prognosis are thus unlimited by 
the technical possibilities of genome study but depend 
on the amount of knowledge on a phenome and its ge-
netic determinants. 
Data on complete genomes are insufficient at the mo-
ment in order to systematize the layout of interpopula-
tion differences on a genome-wide scale; however, the 
existence of interindividual and interracial differences 
in the number of MFD-associated markers is obvious. 
Thus, Venter’s genome has about 50 SNPs which are 
associated with alcoholism. The sequenced Yoruba ge-
nome has 30, Watson - 25, and the Mongoloids (Chinese, 
Korean, and ancient Eskimo) have less than 20. Ven-
ter is also a record-holder in terms of SNPs associated 
with tobacco addiction (about 40 SNPs). The Chinese 
and ancient Greenlander have about 20 of these mark-
ers, while Watson’s genome, as well as the Korean and 
Yoruba genomes, has none. 
Table 5. Characteristics of six individual genomes
Genome Ethnic origin, Country Number 
of SNPs
Overlapping with other genomes by common (%)
HuRef Watson NA18507 YH SJK Saqqaq
HuRef (Venter) White American, U.S. 3075858 100 55.8 52.9 51.6 56.4 34.2
Watson White American, U.S. 3321942 51.6 100 50.8 49.9 54.9 36
NA18507 Yoruba, Nigeria 4189457 38.8 40.3 100 42.1 45.8 27
YH Chinese, China 3074097 51.6 54 57.3 100 67.3 38.2
SJK Korean, South Korea 3439107 50.5 53 55.8 60.1 100 39
Saqqaq Paleo-Eskimo, Greenland 2193396 47.9 33.9 32.5 53.5 61.1 100
Watson
Venter
CEU
YRI
CHB+JPT
YH
Fig 4. Individual genomes of Venter, Watson, and a 
Chinese individual (YH) on the tree of HapMap individuals 
(according to [88], with alterations).26 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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The most complete approach to using genome-scale 
information for making individual health prognoses 
was demonstrated in the recent work of Ashley et al. 
[108]. In order to estimate the risk of a certain disease, 
they proposed the use of a so-called pretest risk as a 
baseline. This pretest risk is an epidemiological risk 
estimate, which can in its simplest form be the inci-
dence of this disease in the appropriate ethnic and 
age group. The individual genome was then tested for 
SNPs, which are reliably associated with the disease 
according to GWAS data. Based on these data, the re-
searchers calculated post-test risk, which views each 
marker as an independent risk factor. An example cal-
culation of the individual risk of myocardial infarc-
tion is shown in Table 6. The risk was estimated for a 
healthy 40-year-old white American, whose genome 
was sequenced in study [92]. The DNA donor had a 
family history of cardio-vascular diseases and some 
cases of sudden death among relatives. His biochemi-
cal and electrocardiogram parameters were normal. 
The pretest risk was estimated at 2%. The individual’s 
genome contained 7 SNPs which were reliably associ-
ated with myocardial infarction according to GWAS 
data. The OR (genetic risk estimate) values of the 
individual’s genotypes varied from 0.75 to 2.86. The 
overall risk of myocardial infarction (product of the 
pretest risk and OR of each marker) was 8.9%. In this 
case, the genetic composition of the tested individual 
increased the overall risk by 4.5-fold as compared with 
the pretest risk. 
CONCLUSION
Humans display a relatively low level of genetic vari-
ability (both at the level of population differentiation 
and at the level of individual genomes), which is set on 
a background of high phenotypic variability and strict 
geographical structure of the genetic variation, which 
is manifested in the clustering of geographically adja-
cent populations. The spatial nature of the genetic vari-
ability distribution of modern humans can be observed 
at different levels of population structure and in vari-
ous groups of markers, including the genes associated 
with MFD development. Genetic differences between 
human populations are responsible for only 10-15% of 
the genetic variability in humans. However, these dif-
ferences prove significant in the field of personalized 
medicine in terms of diagnosing monogenic diseases, 
estimating the susceptibility to common diseases, and 
making health prognoses, and the efficiency of drug 
therapy. 
Returning to the issues stated in the introduction, 
let’s sum up our current knowledge. Genetic differen-
tiation in populations for disease genes is as large as the 
overall level of interpopulation diversity on a genome-
wide scale. Observed interethnic differences in the inci-
dence of human diseases can be almost completely (for 
Mendelian diseases) or to a significant degree (for MFD) 
explained by the different frequencies of disease-asso-
ciated genes. The general “geographical pattern” of ge-
netic diversity took shape during the spread of modern 
humans through migrations, genetic drift, and sudden 
changes in the effective size of populations. However, 
natural selection could have played a significant role in 
the development of the variability of some regions of 
the genome both on a global scale (such as the immune 
response or skin pigmentation gene) or at the level of 
population adaptations to the local environment (such 
as genes for metabolizing compounds present in the 
diet). The biological effects of distinct genetic variants 
(mutations of polymorphisms) in relation to disease are 
usually stable and do not depend on the racial, ethnic, 
or geographic context. However, the magnitude of the 
effects (the relative role of the marker in the disease 
itself or in the risk of disease development) can exhibit 
strong variation at the population and individual levels 
due to the different genetic (haplotypic) environment 
and modifying gene-gene and gene-environment in-
teractions. 
Undoubtedly, the “ethnic factor” must be taken into 
account during medical studies, especially those con-
cerning personalized genomic medicine. The long his-
tory of discussions on this issue in medical and genetic 
literature continues (see [36, 109–111]). However, the 
professional community of researchers who work in the 
field of personal genomics devotes considerable atten-
tion to population aspects both at the stage of data col-
lection (such as the GWAS or pharmacogenomic stud-
ies) and at the data-interpretation stage of individual 
genetic testing or genetic screening at the population 
level [110]. 
Table 6. Individual calculation of myocardial infarction risk 
based on genomic data (according to [108])
Gene SNP Genotype OR
Risk, %
Pretest
Post-test
LPA rs3798220 CT 1.86 3.7
THBS2 rs8089 AC 1.09 4.0
LDLR rs14158 GG 2.88 10.6
LIPC rs11630220 AG 1.15 12.0
ESR2 rs1271572 CC 0.73 9.1
ESR2 rs35410698 GG 1.03 9.4
FXN rs3793456 AA 0.94 8.9REVIEWS
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Integration of genomics and phenomics in the frame-
work of system biology, novel powerful instruments for 
describing and analyzing genetic diversity - sequenc-
ing individual genomes and genome-wide analysis of 
SNP on microarrays, the HapMap and “1000 genomes” 
projects - all of these new happenings give hope as to 
fast progress in the categorization of genetic diversity 
associated with the risk of common diseases, the ef-
ficiency of drug therapy, and the establishment of a 
tight link between basic scientific results and proven 
recommendations for personalized medicine.  
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